Literature DB >> 17312463

Treatment with BX471, a nonpeptide CCR1 antagonist, protects mice against acute pancreatitis-associated lung injury by modulating neutrophil recruitment.

Min He1, Richard Horuk, Madhav Bhatia.   

Abstract

OBJECTIVES: Chemokines and their receptors play a key role in the pathogenesis of acute pancreatitis. BX471 is a potent nonpeptide CC chemokine receptor 1 antagonist in both human and mouse. The aim of the present study was to evaluate the effect of prophylactic and therapeutic treatment with BX471 on experimental acute pancreatitis in the mouse and to investigate the underlying mechanisms.
METHODS: Acute pancreatitis was induced in mice by hourly intraperitoneal injection of cerulein. BX471 was administered either prophylactically or therapeutically, and pancreatic inflammation and lung injury were assessed. The expression of intercellular adhesion molecule 1, P-selectin, and E-selectin was studied by reverse transcriptase-polymerase chain reaction and immunohistochemistry.
RESULTS: In cerulein-induced acute pancreatitis, treatment with BX471 significantly protected mice against lung injury associated with cerulein-induced pancreatitis by attenuating myeloperoxidase activity, an indicator of neutrophil recruitment, and lung morphological changes in histological sections. Treatment with BX471 had little effect on pancreatic damage. Blocking CC chemokine receptor 1 by BX471 also down-regulated intercellular adhesion molecule 1, P-selectin, and E-selectin expression at mRNA and protein levels in both lungs and pancreas compared with vehicle-treated groups.
CONCLUSIONS: These findings suggest that interfering with neutrophil migration and activation by targeting CC chemokine receptor 1 may represent a promising strategy to prevent disease progression in acute pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17312463     DOI: 10.1097/mpa.0b013e31802e7598

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

1.  The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosis.

Authors:  Xuebin Yang; William Walton; Donald N Cook; Xiaoyang Hua; Stephen Tilley; Christopher A Haskell; Richard Horuk; A William Blackstock; Suzanne L Kirby
Journal:  Am J Respir Cell Mol Biol       Date:  2010-09-24       Impact factor: 6.914

Review 2.  Immunomodulatory therapies for acute pancreatitis.

Authors:  Jing Li; Wen-Juan Yang; Lu-Ming Huang; Cheng-Wei Tang
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 3.  Role of chemokines in the pathogenesis of acute lung injury.

Authors:  Madhav Bhatia; Rachel L Zemans; Samithamby Jeyaseelan
Journal:  Am J Respir Cell Mol Biol       Date:  2012-02-09       Impact factor: 6.914

4.  A key role for CC chemokine receptor 1 in T-cell-mediated respiratory inflammation.

Authors:  Matthew A Schaller; Lara E Kallal; Nicholas W Lukacs
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

5.  Interferon-gamma coordinates CCL3-mediated neutrophil recruitment in vivo.

Authors:  Cynthia A Bonville; Caroline M Percopo; Kimberly D Dyer; Jiliang Gao; Calman Prussin; Barbara Foster; Helene F Rosenberg; Joseph B Domachowske
Journal:  BMC Immunol       Date:  2009-03-19       Impact factor: 3.615

6.  Ccr1 deficiency reduces inflammatory remodelling and preserves left ventricular function after myocardial infarction.

Authors:  E A Liehn; M W Merx; O Postea; S Becher; Y Djalali-Talab; E Shagdarsuren; M Kelm; A Zernecke; C Weber
Journal:  J Cell Mol Med       Date:  2007-12-14       Impact factor: 5.310

7.  Effects of blocking chemokine receptor CCR1 with BX471 in two models of fibrosis prevention and rescue in mice.

Authors:  Susanne N Weber; Irina Nowak; Frank Grünhage; Frank Lammert
Journal:  Biochem Biophys Rep       Date:  2021-07-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.